ROLE OF THE HIV TAT GENE IN TRANSFORMATION OF HUMAN KERATINOCYTES IN CULTURE AND INDUCTION OF TUMORS IN TRANSGENIC MICE (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


ROLE OF THE HIV TAT GENE IN TRANSFORMATION OF HUMAN KERATINOCYTES IN CULTURE AND INDUCTION OF TUMORS IN TRANSGENIC MICE (MEETING ABSTRACT)

Workshop on Neoplastic Transformation in Human Cell Systems In Vitro: Mechanisms of Carcinogenesis, April 25-26, 1991, Washington, DC, p. S14, 1991.. Unique Identifier : AIDSLINE ICDB/92678305
Jay G; Vogel J; Kim CM; Rhim JS; Lab. of Virology, Jerome H. Holland Lab., Rockville, MD


Abstract: Patients (pts) with the acquired immunodeficiency syndrome (AIDS) frequently present with cutaneous disorders, such as Kaposi's sarcoma, psoriasis, squamous cell carcinoma, basal cell carcinoma, and melanoma. Since these individuals are frequently infected not only by the human immunodeficiency virus (HIV) but also by other agents including the human papilloma virus, it is not clear whether the development of any of these skin manifestations is directly attributable to HIV. Given that HIV carries a potent transactivator gene, designated tat, which acts to regulate viral genes, we reasoned that it may also perturb the expression of cellular genes leading ultimately to the development of disease. To explain the psoriatic lesions detected in AIDS pts, we ask whether the HIV tat gene under the control of its own regulatory element (LTR) will transform epidermal keratinocytes in culture. We observed that human keratinocytes transfected with this gene alone showed extensive morphological alterations, grew efficiently in soft agar, and induced tumors in nude mice. This observation would suggest that the psoriatic lesions detected in HIV-infected individuals may be directly caused by the expression of viral genes in the proliferating keratinocytes. As a further analysis, we have introduced the same HIV tat gene under the control of the viral LTR into the germline of mice in order to define HIV pathogenesis in the context of a whole animal. The resulting transgenic mice showed selective expression of the tat gene in the epidermis and, as early as 3-4 mo of age, showed extensive epidermal hyperplasia. Despite the restricted expression of the transgene in the epidermis, these mice went on to develop progressive dermal lesions with features characteristic of human Kaposi's sarcoma and thus confirming the involvement of the tat gene in this form of malignancy. We propose that HIV is responsible for at least some of the cutaneous manifestations observed in AIDS pts and offer differing mechanisms whereby the HIV tat gene may act on diverse target cells in the skin to induce uncontrolled proliferation both in culture and in animals.
Keywords: Acquired Immunodeficiency Syndrome/MICROBIOLOGY Animal *Cell Transformation, Neoplastic Cells, Cultured *Genes, tat Human HIV/*GENETICS HIV Long Terminal Repeat Keratinocytes/*CYTOLOGY/PATHOLOGY Mice Mice, Transgenic Skin Neoplasms/*GENETICS/PATHOLOGY ABSTRACTKWDacquiredimmunodeficiencysyndrome/microbiologyanimalKWDcelltransformation,neoplasticcells,culturedKWDgenes,tathumanhiv/KWDgeneticshivlongterminalrepeatkeratinocytes/KWDcytology/pathologymicemice,transgenicskinneoplasms/KWDgenetics/pathologyabstract
920228
M9220883

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .